


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claim 1. (Currently amended): A topical pharmaceutical composition comprising a lavendustin derivative of formula I



wherein R is methyl, methoxy or ethyl, or a pharmaceutically acceptable salt thereof; [, and] an emollient; optionally, a hydrophilic component; and, optionally, water.

Claim 2. (Currently amended): A composition according to claim 1 wherein the emollient is isopropyl myristate.


Claim 3. (Original): A composition according to claim 1 in the form of an emulsion.

Claim 4. (Original): A composition according to claim 3 in the form of an oil-in-water emulsion.

Claim 5. (Previously presented): A topical pharmaceutical composition according to claim 1 which avoids high local concentration of the lavendustin in the skin or mucous membrane and is well tolerated.

Claim 6. (Currently amended): A process for the preparation of a composition according to claim 1, comprising

(a) dissolving a lavendustin derivative of formula I



wherein R is methyl, methoxy or ethyl, or a pharmaceutically acceptable salt thereof, and
optionally, a hydrophilic component, as defined in claim 1, or a pharmaceutically acceptable salt
thereof, in an emollient and optionally further lipophilic components such as consistency agents,
if present, preferably at elevated temperature, e.g. at from about 60 to about 80 °C, and,
optionally,

(b) adding the water phase, if present, under stirring and homogenization.

Claims 7-8. (Canceled)

Claim 9. (Currently amended): A method for the [[of]] treatment of hyperproliferative disorders such as actinic keratosis, anogenital warts and seborrheic keratosis, and skin cancer comprising administering a composition according to claim 1 to the skin or mucous membrane of a patient in need thereof.

Claim 10. (New): A composition according to claim 1 wherein the emollient comprises liquid fatty alcohols, oleyl alcohol, liquid waxes, isopropyl myristate, oleyl erucate, diisopropyl adipate, oleyl oleate, diglycerides having C₈ to C₂₄ fatty acids, triglycerides having C₈ to C₂₄ fatty acids fatty acids, Miglyol® 812, propylene glycol mono-fatty acid esters, propylene glycol di-fatty acid esters, propylene glycol caprylate, propylene glycol dilaurate, propylene glycol hydroxystearate, propylene glycol isostearate, propylene glycol laurate, propylene glycol ricinoleate, and propylene glycol stearate, petrolatum, or mixtures thereof.

Claim 11. (New): A composition according to claim 1 wherein the lavendustin derivative is present in an amount of from about 0.01% to about 10% by weight based on the total weight of the composition.

Claim 12. (New): A composition according to claim 1 wherein emollient is present in an amount of about 1% to about 40% by weight based on the total weight of the composition.

Claim 13. (New): A composition accordingly to claim 1 wherein the hydrophilic component comprises propylene glycol, hexylene glycol, liquid polyethylene glycol, glycerol, or mixtures thereof.

Claim 14. (New): A composition according to claim 1 wherein hydrophilic component is present in an amount of about 1% to about 20% by weight based on the total weight of the composition.

Claim 15. (New): A composition according to claim 3 in the form of a water-in-oil emulsion.

Claim 16. (New): A composition according to claim 1 wherein the water is present in an amount of from about 20% to about 80% by weight based on the total weight of the composition.

Claim 17. (New): A composition according to claim 1 wherein the compound comprising a lavendustin derivative of formula I is 6-[2-(2,5-dimethoxyphenyl)ethyl]-4-ethyl-quinazoline.

Claim 18. (New): The process of claim 6 wherein the temperature is from about 60°C to about 80°C.

Claim 19. (New): The method of claim 9 wherein the hyperproliferative disorder is selected from the group consisting of actinic keratosis, anogenital warts and seborrhoic keratosis.